Fusion Pharmaceuticals (FUSN) Revenue & Revenue Breakdown
Fusion Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$2.07M
Fusion Pharmaceuticals Revenue by Period
Fusion Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.07M | 41.55% |
| 2022-12-31 | $1.46M | 1.46% |
| 2021-12-31 | $1.44M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Fusion Pharmaceuticals generated $2.07M in revenue during NA 2023, up 41.55% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Fusion Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $33.64M | 1576.77% |
| 2023-09-30 | $2.01M | 5800.00% |
| 2023-06-30 | $34.00K | 21.43% |
| 2023-03-31 | $28.00K | -80.00% |
| 2022-12-31 | $140.00K | -15.66% |
| 2022-09-30 | $166.00K | -70.88% |
| 2022-06-30 | $570.00K | -2.56% |
| 2022-03-31 | $585.00K | -1.52% |
| 2021-12-31 | $594.00K | 82.77% |
| 2021-09-30 | $325.00K | -37.62% |
| 2021-06-30 | $521.00K | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Fusion Pharmaceuticals generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Fusion Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| BCYC | Bicycle Therapeutics | $26.98M | $9.36M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| IKNA | Ikena Oncology | $9.16M | - |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| FUSN | Fusion Pharmaceuticals | $2.07M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| RAPT | RAPT Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| BCAB | BioAtla | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| PASG | Passage Bio | - | - |
| NLTX | Neurogene | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| RLMD | Relmada Therapeutics | - | - |
FUSN Revenue FAQ
What is Fusion Pharmaceuticals’s yearly revenue?
Fusion Pharmaceuticals's yearly revenue for 2023 was $2.07M, representing an increase of 41.55% compared to 2022. The company's yearly revenue for 2022 was $1.46M, representing an increase of 1.46% compared to 2021. FUSN's yearly revenue for 2021 was $1.44M, representing an increase of 100.00% compared to 2020.
What is Fusion Pharmaceuticals’s quarterly revenue?
Fusion Pharmaceuticals's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $33.64M, a 1576.77% increase from the previous quarter (Q3 2023), and a 23925.71% increase year-over-year (Q4 2022). FUSN's quarterly revenue for Q3 2023 was $2.01M, a 5800.00% increase from the previous quarter (Q2 2023), and a 1108.43% increase year-over-year (Q3 2022).
What is Fusion Pharmaceuticals’s revenue growth rate?
Fusion Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 43.61%, and for the last 5 years (2019-2023) was 0%.